App-Quantinova.ai

A bayesian network meta-analysis of different agents or regimens as second-line treatment for SCLC.

Qihua He - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Topotecan Hydrochloride

Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations.

Huarong Tang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer.

Haiyan Zeng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

FGFR1 protein overexpression as a prognosis marker for operated small cell lung cancer patients.

Xie Fa Jun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

1p19q codeletion and RET rearrangements in small cell lung cancer.

Hongyang Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

O(6)-methyl-guanine-DNA promoter methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.

Hongyang Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.

Yi-Long Wu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

gefitinib

The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis.

Qing Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epitinib

Atypical negative ALK FISH accompanied by immunohistochemistry positivity harbored various ALK rearrangements in NSCLC patients and respond to targeted therapy.

Jianming Ying - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

First-line icotinib in elderly patients with non-small cell lung cancer harboring active EGFR mutation: A multi-center, single-arm study.

Chunlei Shi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Icotinib

Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.

Enriqueta Felip - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Ceritinib

A c-met inhibitor in the treatment of metastatic non small cell lung cancer with c-met amplification.

Tongtong Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Crizotinib

Association of glucocorticoid receptor expression with the treatment outcome of pemetrexed-based chemotherapy in NSCLC patients.

Xinmin Zhao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Glucocorticoid

A bayesian network comparison of different agents or regimens as first-line treatment for advanced EGFR-mutated NSCLC.

Wenhua Liang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Continuation of epidermal growth factor tyrokine kinase inhibitor with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients.

Ling Peng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Prognostic ability of miR-744 expression in non-small cell lung cancer (NSCLC).

Xiaoxia Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.

Meijuan Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Carboplatin

Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.

Jin-Ji Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Savolitinib

Efficacy of aggressive thoracic therapy (ATT) compared with no ATT for synchronous oligometastatic non-small cell lung cancer (NSCLC): Results of a meta-analysis.

Xiaoxia Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Correlation of PD-L1 expression with EGFR, KRAS, or ALK alterations and with survival of non-small cell lung cancer (NSCLC) treated with EGFR-TKIs: A meta-analysis of published trials.

Dianhe Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Filters

24782 Abstracts